Organovo (Nasdaq: ONVO) gives business update on its focus in developing treatments for inflammatory bowel disease.
In San Diego on March 27, 2025, Organovo Holdings, Inc. (Nasdaq: ONVO) shared a business update. The company, a clinical stage biotech firm, specializing in innovative treatments for inflammatory bowel disease (IBD), detailed their recent developments.